About this trial
In patients with type II diabetes mellitus (T2DM) and obesity, an excess plasma-free fatty acid is found with an associated increased lipid accumulation in adipocytes and liver tissue. Lipid droplet accumulation in the hepatocytes is an initial step in the development of metabolic dysfunction associated steatotic liver disease (MASLD. Insulin resistance, which is associated with T2DM, mediates the inflammation of these lipids, resulting in the progression of MASLD to metabolic dysfunction associated steatotic hepatitis (MASH). Hence, in T2DM, obesity, and MASLD, changes in the lipid profile occur, and they are interrelated.
In this study, we aim to assess improvement in the lipidomic, its associated metabolic changes and evaluate the co-regulated genes in the liver tissue among patients with MASLD with intervention with GLP-1 RA, which has shown to benefit T2DM and obesity.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
known diagnosis of MASLD by histology, also have diabetes/ obesity
on treatment with GLP-1 RA at stable dose
Disqualifiers
unable to have a liver biopsy, recent change in medication for diabetes or hyperlipidemia
on immunosuppression, liver or kidney transplant
pregnancy
Trial population
known diagnosis of MASLD by histology, also have diabetes/ obesity
Trial design
Cohort
Prospective
Treatments tested in this trial
GLP-1 receptor agonist
Drugon and not on treatment
Treatment groups
Trial outcomes
Primary outcomes
Changes in lipidomics profile on use of GLP-1 RA
Lipidomic profile being evaluated
Secondary outcomes
Changes in associated proteomics and transcriptomics with the use of GLP-1 RA
proteomic and transcriptomics profiles evaluated
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: